Stryker Corporation (SYK)
| Market Cap | 130.83B -9.1% |
| Revenue (ttm) | 25.84B +8.5% |
| Net Income | 3.73B +27.8% |
| EPS | 9.65 +27.8% |
| Shares Out | 383.57M |
| PE Ratio | 35.35 |
| Forward PE | 21.26 |
| Dividend | $3.52 (1.03%) |
| Ex-Dividend Date | Sep 30, 2026 |
| Volume | 2,017,200 |
| Open | 345.02 |
| Previous Close | 347.21 |
| Day's Range | 339.53 - 346.64 |
| 52-Week Range | 281.00 - 396.86 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 382.88 (+12.25%) |
| Earnings Date | Jul 30, 2026 |
About SYK
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally inv... [Read more]
Financial Performance
In 2025, Stryker's revenue was $25.12 billion, an increase of 11.16% compared to the previous year's $22.60 billion. Earnings were $3.25 billion, an increase of 8.45%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for SYK stock is "Buy." The 12-month stock price target is $382.88, which is an increase of 12.25% from the latest price.
News
Stryker declares an $0.88 per share quarterly dividend
Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholder...
Stryker price target lowered to $400 from $440 at Citizens
Citizens analyst David Turkaly lowered the firm’s price target on Stryker (SYK) to $400 from $440 and keeps an Outperform rating on the shares. Stryker’s FY26 has faced unusual disruptions…
Stryker price target lowered to $420 from $435 at RBC Capital
RBC Capital analyst Shagun Singh lowered the firm’s price target on Stryker (SYK) to $420 from $435 and keeps an Outperform rating on the shares after its Q2 results and…
Stryker price target lowered to $370 from $383 at Raymond James
Raymond James lowered the firm’s price target on Stryker (SYK) to $370 from $383 and keeps an Outperform rating on the shares. Stryker’s Q2 results were impacted by unexpected NARI…
Stryker price target lowered to $358 from $371 at BTIG
BTIG analyst Ryan Zimmerman lowered the firm’s price target on Stryker (SYK) to $358 from $371 and keeps a Buy rating on the shares. The major focus for the quarter…
Stryker price target lowered to $350 from $400 at JPMorgan
JPMorgan analyst Robbie Marcus lowered the firm’s price target on Stryker (SYK) to $350 from $400 and keeps an Overweight rating on the shares.
Stryker price target lowered to $390 from $420 at Piper Sandler
Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Stryker (SYK) to $390 from $420 and keeps an Overweight rating on the shares. The firm notes Stryker reported…
Stryker beats quarterly estimates on strong demand for medical devices
U.S. medical device maker Stryker on Thursday beat Wall Street estimates for second-quarter results, aided by strong demand for its implants and devices used in complex procedures ranging from spina...
Stryker Logs Higher Profit, Revenue Amid Cyberattack Recovery
The medical technology company reported a profit of $1.28 billion and and said it has made progress in recovering from a March cyberattack.
Stryker Earnings Call Transcript: Q2 2026
Second quarter results showed 9% organic sales growth and 17.9% adjusted EPS growth year-over-year, driven by strong demand, operational recovery post-cyber incident, and robust capital orders. Guidance for 2026 was narrowed, reflecting confidence in production ramp and backlog realization.
Stryker Earnings release: Q2 2026
Stryker released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Stryker Quarterly report: Q2 2026
Stryker has published its Q2 2026 quarterly earnings report on July 30, 2026.
Stryker reports Q2 adjusted EPS $3.69, consensus $3.49
Reports Q2 revenue $6.59B, consensus $6.58B. “We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in…
Stryker sees FY26 adjusted EPS $14.95-$15.10, consensus $14.97
Additionally, foreign exchange is expected to have a slightly favorable impact on both sales and adjusted net earnings per diluted share should rates hold near current levels. Published first on…
Stryker reports second quarter 2026 operating results
Portage, Michigan, July 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2026:
Stryker assumed with Buy from Neutral at UBS
UBS upgraded Stryker (SYK) to Buy from Neutral with a price target of $400, up from $380, after assuming coverage of the name. Survey work suggests worries around the company’s…
Stryker announces U.S. commercial launch of Mako RPS
Stryke announced the U.S. commercial launch of Mako RPS for total knee replacement procedures, further expanding the Mako portfolio into a new category of orthopaedic robotics. The launch marks the…
Stryker expands Mako robotics portfolio with full market release of Mako RPS
New handheld robotic technology expands the Mako platform and brings Mako robotic-assisted knee replacement to a new segment of the orthopaedic market Stryker announced the U.S. commercial launch of M...
Booking, Alphabet, and 7 Other Stocks to Buy Ahead of Earnings
Booking Holdings, Alphabet, and six other companies have underperformed their sectors despite improving earnings expectations, setting up potential upside during second-quarter earnings season.
Stryker price target lowered to $371 from $379 at BTIG
BTIG lowered the firm’s price target on Stryker (SYK) to $371 from $379 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
Stryker price target raised to $370 from $350 at Argus
Argus raised the firm’s price target on Stryker (SYK) to $370 from $350 and keeps a Buy rating on the shares. The firm is confident that the company will be…
Stryker initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Stryker (SYK) with an Outperform rating and $369 price target The March 2026 cyberattack was an operational disruption, not a demand story, and hospital order…
Buy these quality, low-stress stocks for the summer, says Jefferies
Markets have become more volatile as investors debate whether big tech companies are getting enough return on their AI spending. The S&P 500 momentum index has outperformed the wider market by more th...
Stryker price target lowered to $350 from $355 at Evercore ISI
Evercore ISI lowered the firm’s price target on Stryker (SYK) to $350 from $355 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life Sciences…
Stryker to announce second quarter 2026 financial results
Portage, Michigan, July 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, July 30, 2026, to discuss its second quarter 2026 financial result...